Prognostic value of microRNA expression in operable non-small cell lung cancer patients

British Journal of Cancer

Volumn 110, Issue 4, 2014, Pages 991-1000

  Skrzypski, M ^a   Czapiewski, P ^b   Goryca, K ^c   Jassem, E ^b   Wyrwicz, L ^c   Pawlowski R ^a   Rzyman, W ^a   Biernat, W ^b   Jassem, J ^a  

^a UNIVERSITY OF GDA SK   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84894346524     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.786     Document Type: Article

References (41)

1. Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS (2006) K-ras mutations in non-small-cell lung carcinoma: A review. Clin Lung Cancer 8(1): 30-38.
2. Bepler G, Olaussen KA, Vataire AL, Soria JC, Zheng Z, Dunant A, Pignon JP, Schell MJ, Fouret P, Pirker R, Filipits M, Brambilla E (2011) ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. Am J Pathol 178(1): 69-78.
3. Calin GA, Croce CM (2006) MicroRNA-cancer connection: The beginning of a new tale. Cancer Res 66(15): 7390-7394.
4. Chee KG, Nguyen DV, Brown M, Gandara DR, Wun T, Lara PN (2008) Positron emission tomography and improved survival in patients with lung cancer: The Will Rogers phenomenon revisited. Arch Intern Med 168(14): 1541-1549.
5. Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao MS, Graziano S, Kratzke R, Douillard JY, Seymour L, Pirker R, Filipits M, André F, Solary E, Ponsonnailles F, Robin A, Stoclin A, Dorvault N, Commo F, Adam J, Vanhecke E, Saulnier P, Thomale J, Le Chevalier T, Dunant A, Rousseau V, Le Teuff G, Brambilla E, Soria JC (2013) ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 368(12): 1101-1110.
6. Guo N, Wan Y, Tosun K, Lin H, Msiska Z, Flynn D, Remick S, Vallyathan V, Dowlati A, Shi X, Castranova V, Beer D, Qian Y (2008) Confirmation of gene expression-based prediction of survival in non-small cell lung cancer. Clin Cancer Res 14(24): 8213-8220.
7. Hall JS, Taylor J, Valentine HR, Irlam JJ, Eustace A, Hoskin PJ, Miller CJ, West CM (2012) Enhanced stability of microRNA expression facilitates classification of FFPE tumour samples exhibiting near total mRNA degradation. Br J Cancer 107(4): 684-694.
8. Huncharek M, Kupelnick B, Geschwind JF, Caubet JF (2000) Prognostic significance of p53 mutations in non-small cell lung cancer: A metaanalysis of 829 cases from eight published studies. Cancer Lett 153(1-2): 219-226.
9. Jin Z, Selaru FM, Cheng Y, Kan T, Agarwal R, Mori Y, Olaru AV, Yang J, David S, Hamilton JP, Abraham JM, Harmon J, Duncan M, Montgomery EA, Meltzer SJ (2011) MicroRNA-192 and-215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression in vitro. Oncogene 30(13): 1577-1585.
10. Jung DE, Wen J, Oh T, Song SY (2011) Differentially expressed microRNAs in pancreatic cancer stem cells. Pancreas 40(8): 1180-1187.
11. Kratz JR, He J, Van Den Eeden SK, Zhu ZH, Gao W, Pham PT, Mulvihill MS, Ziaei F, Zhang H, Su B, Zhi X, Quesenberry CP, Habel LA, Deng Q, Wang Z, Zhou J, Li H, Huang MC, Yeh CC, Segal MR, Ray MR, Jones KD, Raz DJ, Xu Z, Jahan TM, Berryman D, He B, Mann MJ, Jablons DM (2012) A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: Development and international validation studies. Lancet 379(9818): 823-832.
12. Landi M, Zhao Y, Rotunno M, Koshiol J, Liu H, Bergen A, Rubagotti M, Goldstein A, Linnoila I, Marincola F, Tucker M, Bertazzi P, Pesatori A, Caporaso N, McShane L, Wang E (2010) MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res 16(2): 430-441.
13. Livak K, Schmittgen T (2001) Analysis of relative gene expression data using real-Time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4): 402-408.
14. Lu Y, Govindan R, Wang L, Liu PY, Goodgame B, Wen W, Sezhiyan A, Pfeifer J, Li YF, Hua X, Wang Y, Yang P, You M (2012) MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. Carcinogenesis 33(5): 1046-1054.
15. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93(4): 387-391.
16. Meissner TB, Li A, Biswas A, Lee KH, Liu YJ, Bayir E, Iliopoulos D, Van Den Elsen PJ, Kobayashi KS (2010) NLR family member NLRC5 is a transcriptional regulator of MHC class I genes. Proc Natl Acad Sci USA 107(31): 13794-13799.
17. Michiels S, Koscielny S, Hill C (2005) Prediction of cancer outcome with microarrays: A multiple random validation strategy. Lancet 365(9458): 488-492.
18. Network CGAR (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489(7417): 519-525.
19. Pepek JM, Chino JP, Marks LB, Damico TA, Yoo DS, Onaitis MW, Ready NE, Hubbs JL, Boyd J, Kelsey CR (2011) How well does the new lung cancer staging system predict for local/regional recurrence after surgery?: A comparison of the TNM 6 and 7 systems. J Thorac Oncol 489(7417): 519-525.
20. Pignon J, Tribodet H, Scagliotti G, Douillard J, Shepherd F, Stephens R, Dunant A, Torri V, Rosell R, Seymour L, Spiro S, Rolland E, Fossati R, Aubert D, Ding K, Waller D, Le Chevalier T, Group LC (2008) Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol 26(21): 3552-3559.
21. Raponi M, Dossey L, Jatkoe T, Wu X, Chen G, Fan H, Beer D (2009) MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res 69(14): 5776-5783.
22. Raponi M, Zhang Y, Yu J, Chen G, Lee G, Taylor JM, Macdonald J, Thomas D, Moskaluk C, Wang Y, Beer DG (2006) Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 66(15): 7466-7472.
23. Schmittgen T, Livak K (2008) Analyzing real-Time PCR data by the comparative C(T) method. Nat Protoc 3(6): 1101-1108.
24. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1): 11-30.
25. Skrzypski M, Dziadziuszko R, Jassem E, Szymanowska-Narloch A, Gulida G, Rzepko R, Biernat W, Taron M, Jelitto-Górska M, Marjański T, RzymanW, Rosell R, Jassem J (2013) Main histologic types of non-small-cell lung cancer differ in expression of prognosis-related genes. Clin Lung Cancer 14(6): 666-673.e2.
26. Sobin LH, Wittekind C (2002) TNM Classification of Malignant Tumours. 6th edn. John Wiley & Sons: Hoboken, NJ, USA.
27. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, Mitsudomi T, Takahashi T (2004) Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64(11): 3753-3756.
28. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC (eds) (2004) World Health Organization Classification of Tumors. Pathology and Genetics. Tumours of the Lung, Pleura, Thymus and Heart. IARC Press: Lyon, France.
29. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6(2): 244-285.
30. Uehara N, Matsuoka Y, Tsubura A (2008) Mesothelin promotes anchorageindependent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells. Mol Cancer Res 6(2): 186-193.
31. van Vliet MH, Reyal F, Horlings HM, Van De Vijver MJ, Reinders MJ, Wessels LF (2008) Pooling breast cancer datasets has a synergetic effect on classification performance and improves signature stability. BMC Genomics 9: 375.
32. Warth A, Muley T, Meister M, Stenzinger A, Thomas M, Schirmacher P, Schnabel PA, Budczies J, Hoffmann H, Weichert W (2012) The novel histologic International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 30(13): 1438-1446.
33. Wei JS, Johansson P, Chen QR, Song YK, Durinck S, Wen X, Cheuk AT, Smith MA, Houghton P, Morton C, Khan J (2009) microRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies. Clin Cancer Res 15(17): 5560-5568.
34. Wilkerson MD, Yin X, Hoadley KA, Liu Y, Hayward MC, Cabanski CR, Muldrew K, Miller CR, Randell SH, Socinski MA, Parsons AM, Funkhouser WK, Lee CB, Roberts PJ, Thorne L, Bernard PS, Perou CM, Hayes DN (2010) Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clin Cancer Res 16(19): 4864-4875.
35. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, Fry W, Bethune D, Ayoub J, Ding K, Seymour L, Graham B, Tsao MS, Gandara D, Kesler K, Demmy T, Shepherd F. National Cancer Institute of Canada Clinical Trials Group, National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators (2005) Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352(25): 2589-2597.
36. Wu JM, Fackler MJ, Halushka MK, Molavi DW, Taylor ME, Teo WW, Griffin C, Fetting J, Davidson NE, De Marzo AM, Hicks JL, Chitale D, Ladanyi M, Sukumar S, Argani P (2008) Heterogeneity of breast cancer metastases: Comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 14(7): 1938-1946.
37. Xie Y, Xiao G, Coombes KR, Behrens C, Solis LM, Raso G, Girard L, Erickson HS, Roth J, Heymach JV, Moran C, Danenberg K, Minna JD, Wistuba II (2011) Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients. Clin Cancer Res 17(17): 5705-5714.
38. Yamamoto M, Cid E, Bru S, Yamamoto F (2011) Rare and frequent promoter methylation, respectively, of TSHZ2 and 3 genes that are both downregulated in expression in breast and prostate cancers. PLoS One 6(3): E17149.
39. Ying SY, Lin SL (2009) Intron-mediated RNA interference and microRNA biogenesis. Methods Mol Biol 487: 387-413.
40. Yu S, Chen H, Chang G, Chen C, Chen H, Singh S, Cheng C, Yu C, Lee Y, Chen H, Su T, Chiang C, Li H, Hong Q, Su H, Chen C, Chen W, Liu C, Chan W, Li K, Chen J, Yang P (2008) MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13(1): 48-57.
41. Zhu C, Ding K, Strumpf D, Weir B, Meyerson M, Pennell N, Thomas R, Naoki K, Ladd-Acosta C, Liu N, Pintilie M, Der S, Seymour L, Jurisica I, Shepherd F, Tsao M (2010) Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol 28(29): 4417-4424.